Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (IBIO) is a biotechnology innovator providing end-to-end CDMO services and AI-driven solutions for biotherapeutics development. This page serves as the definitive source for all official company announcements, regulatory filings, and operational updates.
Investors and industry observers will find timely access to earnings reports, strategic partnerships, regulatory milestones, and technology advancements related to iBio's vaccine development and precision antibody platforms. Our curated feed ensures transparent tracking of the company's progress in accelerating biopharmaceutical production from discovery to commercialization.
All content is sourced directly from iBio's corporate communications, maintaining factual accuracy and compliance with financial disclosure standards. Bookmark this page for efficient monitoring of IBIO's developments in artificial intelligence applications for drug discovery, manufacturing expansions, and clinical trial updates.
iBio, a biotech innovator, announced its financial results for Q1 FY2021, reporting revenues of approximately $0.4 million, a 280% increase from the same period last year. The company’s net loss was about $7.5 million, or $0.05 per share. R&D expenses rose to $1.8 million, primarily due to increased laboratory supplies. iBio's revenue backlog stands at $2.4 million, and cash and investments totaled $83.5 million. The company highlights its partnerships and ongoing development of COVID-19 therapeutics as part of its growth strategy.
On November 12, 2020, iBio (NYSE: IBIO) announced its participation in Alliance Global Partners' Virtual Healthcare Symposium on November 19, 2020. The company will engage in one-on-one meetings with institutional investors and join a panel discussing the future of COVID-19 treatments. iBio is recognized for its plant-based biologics manufacturing and is advancing treatments like IBIO-100 for fibrotic diseases. The panel, led by Jim Molloy, will address upcoming diagnostics and therapies following major vaccine developments.
iBio, Inc. (NYSEA:IBIO) announced it will release its fiscal 2021 Q1 financial results on November 16, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss the results and provide corporate updates. Investors can access the live and archived webcast on www.ibioinc.com in the Investors section. iBio specializes in plant-based biologics manufacturing, using its patented FastPharming System to produce monoclonal antibodies, vaccines, and other proteins.
iBio Appoints New COO
iBio has appointed Randy J. Maddux as Chief Operating Officer, effective December 1, 2020. With over 20 years of experience in biologics drug development and manufacturing, Maddux previously held leadership roles at Aptevo Therapeutics and GlaxoSmithKline, where he managed significant manufacturing sites. His expertise in biologics is expected to benefit iBio as it expands its pipeline and contract development and manufacturing services. The company focuses on plant-based biologics through its FastPharming system and has promising products in the pipeline, including treatments for fibrotic diseases.
iBio has appointed Gary Sender to its Board of Directors effective October 14, 2020. He will chair the Audit Committee and join the Compensation Committee. Sender brings over 25 years of financial leadership experience from the pharmaceutical and biotech sectors, currently serving as CFO of Nabriva Therapeutics. He has previously held senior roles at Synergy Pharmaceuticals and Shire Plc.
Sender's expertise is expected to enhance iBio's strategic growth, particularly with its FastPharming® System and proprietary technologies.
iBio has appointed Dr. Alexandra Kropotova as a new Board member, effective October 14, 2020. She will also join the newly formed Science & Technology Committee, chaired by Dr. Philip Russell. Dr. Kropotova brings over 20 years of experience in biopharmaceuticals, having held leadership roles at Teva Pharmaceuticals, Sanofi, and Pfizer. Her expertise includes global clinical development and translational medicine. CEO Tom Isett expressed confidence in her contributions to advancing iBio's initiatives in pulmonology, oncology, and fibrotic diseases.
iBio, a biotech company, has appointed Dr. Linda Armstrong to its Board of Directors and the newly established Science & Technology Committee. Dr. Armstrong brings over 20 years of expertise in respiratory diseases, having previously served as Global Head of Respiratory Development at Novartis. Her experience in biologics development is expected to enhance iBio's respiratory disease portfolio, including COVID-19 therapeutic candidates and IBIO-100 for idiopathic pulmonary fibrosis. iBio aims to leverage her insights to advance its product development initiatives.
iBio, a biotech innovator, reported record revenues of over $1.1 million in Q4 and total revenues of approximately $1.6 million for the fiscal year ended June 30, 2020. This reflects a decrease from $2.0 million in FY 2019, mainly due to timing in service revenues. However, revenue from third-party customers increased by 118%. Operating expenses fell to $15.6 million from $17.8 million, while net loss narrowed to $16.4 million or $0.61 per share. iBio's cash position strengthened, increasing to $83.1 million by September 30, 2020.
iBio, Inc. (NYSE AMERICAN:IBIO) has announced it regained compliance with NYSE American listing standards as of October 1, 2020. This follows the company's resolution of a previous deficiency related to market capitalization. CEO Tom Isett emphasized that the company’s new strategic plan has strengthened its financial position and value drivers. iBio aims to leverage its proprietary technologies, including the FastPharming® System, to develop biological medicines for respiratory diseases, including COVID-19.
iBio has signed a Master Services Agreement with Safi Biosolutions to evaluate the use of its FastPharming System in producing proteins for blood cell therapies. This collaboration aims to enhance the bioprocessing of red blood cells and neutrophil therapies, which are critical for trauma and chemotherapy recovery. Additionally, iBio will invest $1.5 million in Safi via a convertible promissory note, boosting its role in innovative blood products development.
